EHNA

EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2) (IC50=4 μM) and adenosine deaminase (ADA) . EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE) (IC50:0.8 μM (human), 2 μM (porcine myocardium) ), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects[1][2][3].

Product Specifications

CAS Number

[51350-19-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adenosine Deaminase; Influenza Virus; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ehna.html

Smiles

CCCCCC[C@@](N1C2=C(C(N)=NC=N2)N=C1)([H])[C@H](O)C

Molecular Formula

C14H23N5O

Molecular Weight

277.37

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Podzuweit T, et al. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9- (2-hydroxy-3-nonyl) adenine.Cell Signal. 1995 Sep;7 (7) :733-8.|[2]Michie AM, et al. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9- (2-hydroxy-3-nonyl) -adenine (EHNA) and rolipram.Cell Signal. 1996 Feb;8 (2) :97-110.|[3]Blázquez-Bermejo C, et al. Increased dNTP pools rescue mtDNA depletion in human POLG-deficient fibroblasts. FASEB J. 2019 Jun;33 (6) :7168-7179.